Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 76,160 trials in your specialties ()
View trials across your selected specialties

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Hereditary Thyroid Gland Medullary Carcinoma, Multiple Endocrine ...
View Full Trial
INTERVENTION

Drug: Sorafenib Tosylate

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Washington University School of Medicine, Saint Louis, Missouri, United States

Brief Summary

This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to the tissue surrounding the thyroid (locally advanced), or has returned after a period of improvement (recurrent). Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

  • Status
    Recruiting
  • Phase
    Early Phase 1
  • Condition
    Refractory Indolent Adult Non-Hodgkin Lymphoma
View Full Trial
INTERVENTION

Drug: CD19 CAR-T, Drug: CD22 CAR-T, Drug: CD19+CD22 CAR-T, Drug: Fludarabine, Drug: Cyclophosphamide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Brief Summary

This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years.

Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Covid19
View Full Trial
INTERVENTION

Drug: Chloroquine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia

Brief Summary

The purpose of this study is to assess the efficacy and safety of chloroquine prophylaxis on the incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections in healthcare workers exposed to patients with confirmed Coronavirus Disease 2019 (COVID-19)

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Advanced Solid Tumors
View Full Trial
INTERVENTION

Drug: SHR-A1811

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Macquarie University Hospital, Macquarie, New South Wales, Australia

Brief Summary

This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    BCC - Basal Cell Carcinoma, Basal Cell Carcinoma, BCC, Basal Cell...
View Full Trial
INTERVENTION

Drug: Jet injection of ALA, Procedure: Surgical excision, Procedure: Illumination, Other: Incubation

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Brief Summary

The purpose of this study is to find out whether injecting ALA into the skin with a jet-injection device and activating the drug with light is a safe treatment that causes few or mild side effects in people with basal cell carcinoma.

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Diabetes Mellitus, Type 2
View Full Trial
INTERVENTION

Drug: Insulin Icodec

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Novo Nordisk Investigational Site, Graz, Austria

Brief Summary

The aim of the study is to improve clinical outcomes for patients with type 2 diabetes by limiting the burden associated with insulin treatment. Participants will get insulin degludec as well as insulin icodec - Insulin icodec is a new medicine while insulin degludec is commonly used and prescribed by doctors. Participants will administer subcutaneous injections of insulin degludec once daily for at least one week (7 injections) but this period may be extended up to 8 weeks. Thereafter, once weekly subcutaneous injections of insulin icodec will follow, resulting in a total of at least 8 but not more than 16 subcutaneous injections of icodec. The study will last for about 17-32 weeks Participants will have at least 5 in-house visits (where participants will stay at the clinic) and 17 outpatient visits with the study doctor. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Glioma of Spinal Cord, Glioma of Brainstem
View Full Trial
INTERVENTION

Drug: Fludarabine, Drug: Cyclophosphamide, Drug: GD2 CAR T cells

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Lucile Packard Children's Hospital (LPCH), Stanford, California, United States

Brief Summary

The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.

Nilotinib for First-line Newly Diagnosed CML-CP Patients

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Chronic Myeloid Leukemia, Chronic Phase, Nilotinib
View Full Trial
INTERVENTION

Drug: Nilotinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Shenzhen Second People's Hospital, Shenzhen, Guangdong, China

Brief Summary

This is a phase IIIb, multi-centre, single-arm, open-label, prospective study investigating the efficacy and safety of nilotinib as the first-line treatment for the adult patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) in China. Nilotinib 300 mg BID will be provided in this study. The assessment for the primary efficacy endpoint will be performed at 18 months and the rate of patients obtaining MR4.5 will be measured at this time point. Secondary endpoints include the complete hematologic response(CHR) and the rates of major molecular reactions (MMR) by 3, 6, 9,12,18 and 24 months; event free survival (EFS); overall survival (OS).

Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy

  • Status
    Recruiting
  • Phase
    Early Phase 1
  • Condition
    Chemotherapy-Induced Peripheral Neuropathy, Numbness, Tingling, Pain
View Full Trial
INTERVENTION

Other: Questionnaire Administration, Drug: Fingolimod, Drug: Fingolimod Hydrochloride

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic, Rochester, Minnesota, United States

Brief Summary

This early phase I trial studies how well fingolimod works in treating patients with chemotherapy-induced nerve pain (neuropathy). Fingolimod acts by suppressing immune reactions in the brain. This study is being done to see if fingolimod can reduce neuropathy caused by chemotherapy.

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Cluster Headache
View Full Trial
INTERVENTION

Drug: Botulinum toxin type A, Drug: placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Universitaetsklinikum Essen, Essen, Germany

Brief Summary

Cluster headache is a primary headache condition characterized by clusters of one-sided, high-intensity pain attacks. The headache may be episodic or chronic. Treatment options are limited and their effects unsatisfactory. An important nerve pathway involved in the pain attacks has a switching station at the sphenopalatine ganglion (SPG) located in the depth of the facial bones. SPG is a known therapy target for cluster headache. The area can be identified on CT images, but is difficult to access due to its location. Thus, the Multiguide navigation system has been developed to enable precise delivery of the drugs that target SPG activity. In Trondheim, two phase 1 / Phase 2 study have been carried out using botulinum toxin A (Botox®) against SPG in patient with chronic cluster headache and chronic migraine. The results indicate that such a treatment strategy is safe and beneficial. The current study is a randomized, placebo-controlled, triple-blinded study to investigate whether precise single-injection of botulinum toxin A reduces the frequency of attacks in chronic cluster headache .